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The half-life of hCG during chemotherapy may be used to monitor
the effect of chemotherapy in patients with germ cell tumours of
the testis (Klein, 1993; Bosl and Motzer, 1997). Thus, Toner et al
(1990) evaluated the half-life of hCG in 134 patients with testic-
ular cancer and elevated hCG. All patients received cisplatin-
containing chemotherapy. Marker half-life of hCG was deemed to
be satisfactory if the half-life of hCG was less than or equal to 3
days. To calculate the half-life, at least two measurements of hCG
between day 7 and day 90 from start of chemotherapy were used.
The authors concluded that a prolonged half-life of hCG after
chemotherapy identifies patients unlikely to achieve a complete
remission (CR). In a recent study, Gerl et al (1996) confirmed
these findings and concluded that marker half-life analysis
complements pretreatment risk stratification and supports selec-
tion of patients for early dose-intensified chemotherapy. In a retro-
spective study, Motzer et al (1992) reported results from the
treatment of patients with refractory germ cell tumour with high-
dose chemotherapy and autologous bone marrow rescue. Slow
marker decline for hCG (>3 days) after the first two cycles of
cisplatin-based chemotherapy was used to identify patients with
unsatisfactory response to initial treatment. These patients were
changed to high-dose chemotherapy and autologous bone marrow
rescue. Accordingly, Murphy et al (1994) reported that the rate of
serum decline of hCG during the first two cycles of chemotherapy
for advanced germ cell tumour could identify patients who might
benefit from an early change to more intensive therapy. The
acceptable half-life of hCG was defined as less than 3 days. Bosl
and Chaganti (1994) reported that a half-life of hCG longer than
3 days after two cycles of chemotherapy may be used to
predict which patients would obtain less than a CR and accord-
ingly would benefit from intensified treatment. Furthermore, Bosl
and Motzer (1997) stated that a plateau or slow clearance suggests
residual active disease and that persistently elevated serum
concentrations of hCG after initial chemotherapy are associated
with viable, often unresectable, residual germ cell tumours and
should be treated with additional chemotherapy rather than
surgical resection.
On the other hand, patients with a half-life of hCG longer than 3
days during chemotherapy may achieve CR and long-time survival
(Horwich and Peckham, 1984; Andreyv et al, 1993; Stevens et al,
1995; de Wit et al, 1997; Zon et al, 1998). Thus, a prolonged half-
life and persistence of a high plasma concentration may be due to
factors other than release of the hormone from tumour cells. The
chemotherapy itself could, in fact, be responsible for a prolonged
plasma disappearance of hCG. We decided to compare the plasma
disappearance of [125I]hCG injected intravenously with the plasma
disappearance of total hCG (injected plus tumour-derived hCG) to
125I-labelled human chorionic gonadotrophin (hCG) as an
elimination marker in the evaluation of hCG decline
during chemotherapy in patients with testicular cancer
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SummaryThe rate of reduction in the concentration of serum human chorionic gonadotrophin (hCG) following chemotherapy for germ cell
tumours may follow a complex pattern, with longer apparent half-life during later stages of chemotherapy, even in patients treated
successfully. The commonly used half-life of less than 3 days for hCG to monitor the effect of chemotherapy in patients with germ cell tumours
of the testis may represent too simple a model. 125I-labelled hCG was injected intravenously in 27 patients with germ cell tumours and
elevated hCG during chemotherapy. The plasma radioactivity and hCG concentrations were followed. During chemotherapy, the plasma
disappearance of hCG showed a biphasic pattern, with an initial fast and a later slow component in all patients. Using the steep part of the
hCG plasma disappearance curve, five patients who achieved long-term remission had half-lives longer than 3 days (3.6–6.8 days), whereas
four out of five patients not achieving long-term remission had half-lives shorter than 3 days. After the third treatment cycle, eight patients who
achieved long-term remission had hCG half-lives longer than 3 days (7.4–17.0 days). In these patients, the plasma disappearance of
[125I]hCG was equivalent to that of hCG. Thus, the slow decline of hCG represented a slow plasma disappearance rather than a hCG
production from vital tumour cells and could, consequently, not be used to select patients for additional or intensified chemotherapy. The
concept of a fixed half-life for plasma hCG during treatment of hCG-producing germ cell tumours is inappropriate and should be revised.
Difficulties in interpreting a slow decline of hCG may be overcome by comparing the plasma disappearance of total hCG with the plasma
disappearance of [125I]hCG.
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visualize the disappearance of hCG in patients with germ cell
tumours of the testis receiving chemotherapy.
MATERIALS AND METHODS
In the period from March 1994 to June 1997, patients with
advanced germ cell tumour of the testis and elevated plasma hCG
concentration (> 10 IU l–1) treated at the Department of Oncology,
Aarhus University Hospital, and the Department of Oncology,
Herlev Hospital, University of Copenhagen, were asked to enter
the study. Entry criteria were the following: advanced non-semino-
matous germ cell tumour of the testis classified as stage II or more
or of extragonadal origin, age above 18 years, hCG > 10 IU l–1 and
signed informed consent.
The primary treatment comprised unilateral orchiectomy
followed by chemotherapy with cisplatin 20 mg m–2 days 1–5,
etoposide 100 mg m–2 days 1–5 and bleomycin 15 mg m–2 on days
2, 9 and 16 (PEB) repeated every 3 weeks. Patients classified as
having a poor prognosis received an intensified cisplatin dose of
40 mg m–2. A standard course of treatment consisted of four treat-
ment cycles. Observation and survival time were calculated from
the start of treatment.
Markers
hCG, a-fetoprotein (AFP) and lactate dehydrogenase (LDH) were
measured in all patients, but only hCG is considered in this report.
The plasma disappearance of hCG was studied in two ways: (1)
immunologically by measuring the plasma disappearance of total
hCG and (2) by measuring the rate of plasma disappearance of
[125I]hCG.
Thyroid uptake of 125I was prevented by giving 400 mg potas-
sium iodide orally. [125I]hCG (3 MBq) (Isopharma, Kjeller,
Norway) was then given as a single intravenous bolus injection
when a slow hCG decline was observed, usually between second
and third treatment cycle. As the specific activity of the hCG was
50 MBq mg–1 and the concentration was 3000 IU mg–1, the quan-
tity of additional hCG given was 180 IU. Following this single
bolus injection of radiolabelled hCG, the 125I concentration in
plasma could be followed for up to 175 days. Total radiation dose
following one injection was 0.03 mSv.
Radioactivity was measured in a well counter (COBRA II auto
gamma, Packard, USA) set to detect within the energy range 15–
75 keV. The background activity has been subtracted from all of the
presented data. All plasma samples were counted at the same time
to avoid calculated correction for the decay of 125I. The relative
counting error was less than 5%. Results for 125I concentration are
presented as counts per minute for a 3-ml aliquot of plasma.
Total hCG was measured using a two-site immunometric assay
specific for intact hCG using either time-resolved immuno-
fluorometry with a detection limit of 5 pg ml–1 (0.05 IU l–1)
(Madersbacher et al, 1993) or enzyme-linked immunosorbent
assay (ELISA) with a detection limit of 2 IU l–1 (215 pg ml–1). The
methods were calibrated using the Third International Standard
(3 IS, 75/537; Kallner et al, 1993). Results for hCG concentrations
are presented as IU per l (conversion ratio 1 IU = 108 ng). Plasma
samples for [125I]hCG and hCG measurements were obtained
simultaneously two or three times weekly.
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Figure 1 hCG measured immunologically during and after chemotherapy in 13 patients with initial hCG > 200 IU l–1 (median 12 900 IU l–1, range 120 000 IU l–1)
and continuous remission during follow-up. Arrow indicates completion of the last, i.e. the fourth, cycle of chemotherapy. All patients were alive without evidence
of disease after a median period of 24+ months (range 8+ to 44+ months) after completion of chemotherapy125I-labelled hCG as an elimination marker 1579
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Initial and late hCG half-lives were calculated assuming a
monoexponential disappearance using an iterative non-linear least
square regression. Initial hCG half-life calculations were based on
the median of five measurements (range 3–15), and only values on
the declining part of the disappearance curve after the first cycle of
chemotherapy were used, thus avoiding a potential marker surge.
Late hCG half-life calculations were based on median of eight
measurements (range 4–11) between the third and fourth cycles of
chemotherapy.
All patients were given oral and written information about the
study. The study was approved by the local ethics committees and
the National Board of Health prior to inclusion of patients.
RESULTS
A total of 27 patients entered the study, and the patients were
observed until relapse and/or death or minimally 12 months after
the start of chemotherapy.
Median age was 30 years (range 19–51 years). All patients had a
non-seminomatous tumour, 26 of testicular origin and one of
extragonadal origin. The median observation time from start of
chemotherapy was 29 months (range 13–45 months) in the good-
risk group and 29 months (range 2–48 months) in the poor-risk
group. Twenty-two of the 27 patients were in continuous remission
after a median time from start of treatment of 31 months (range
12–48 months). One patient (no. 27) with metastases to retroperi-
toneum, mediastinum, lungs and brain died during chemotherapy
as a result of treatment-induced toxicity. Four patients had a
relapse. Three of these have died as a result of progressive disease
9 months (no. 11), 13 months (no. 14) and 7 months (no. 22) after
the start of chemotherapy. The remaining patient relapsed with
increasing hCG concentrations 13 months after achieving a
surgical complete remission (SCR). This patient had salvage
chemotherapy and was alive with no evidence of active disease 44
months after start of primary chemotherapy.
hCG
The median initial hCG for all patients was 1995 IU l–1 (range
10–2 120 000 IU l–1). In the 15 good-risk patients, the median
initial hCG was 130 IU l–1 (range 10–37 800 IU l–1). In the 12
poor-risk patients, the initial median hCG was 108 757 IU l–1
(range 64–2 120 000 IU l–1). Eight had a hCG level above
40 000 IU l–1 and six above 100 000 IU l–1 before treatment.
A total of 1438 blood samples were taken. The plasma disap-
pearance of hCG during chemotherapy showed a biphasic pattern,
with an initial fast and a later slow component in all patients. In 18
patients with an initial hCG above 200 IU l–1, hCG could be
followed during the slow phase of plasma disappearance. Among
these, 13 patients became marker negative and had no evidence of
disease or were in continuous remission during follow-up. Figure
1 shows hCG measurements in these 13 patients. All had finished
treatment on day 80. The points depict a biphasic pattern with an
initial fast decline, corresponding to a half-life of 1.5–3.8 days to
the level of 0.1% of the initial value. In the following prolonged
hCG decline, each of these 13 patients had a half-life for hCG
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Figure 2 Patient no. 2 with an initial hCG plasma concentration of 137 500 IU l–1 receiving four cycles of high-dose PEB. Arrows indicate start of each cycle.
[125I]hCG was injected after completion of the second cycle of chemotherapy. The curves have a similar shape before start of the third cycle of chemotherapy.
The patient only received four cycles of chemotherapy in spite of increased hCG plasma concentration and a prolonged half-life of hCG after the last cycle. At
day 132, a residual retroperitoneal tumour was removed from retroperitoneum by retroperitoneal lymph node dissection (RPLND). Pathology showed necrosis
without malignant cells. Thus, the patient achieved an SCR. The patient was alive with no evidence of disease 48+ months after initiation of chemotherapy1580 TB Christensen et al
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plasma disappearance longer than 3 days irrespective of the initial
hCG concentration and risk status. Four of the five patients who
did not achieve continuous remission had a similar hCG plasma
disappearance pattern during chemotherapy, as described for
patients who achieved a continuous remission. In the remaining
patient (no. 22) who did not achieve continuous remission, hCG
increased between the last two cycles of chemotherapy.
After injection of [125I]hCG, the disappearance curve of
[125I]hCG showed a biphasic pattern with initial fast and a later
slow component. The initial fast phase represents a situation of,
simultaneously, distribution of [125I]hCG into and elimination from
the distribution volume. Thereafter, the plasma disappearance of
[125I]hCG mimics the final prolonged hCG decline. In the 13
patients from Figure 1 with an initial hCG > 200 IU l–1, the final
prolonged hCG decline followed the decline of [125I]hCG for each
individual patient, as exemplified in Figure 2. All of these 13
patients achieved continuous remission.
Four patients had a relapse. In two of these (nos. 11 and 14), the
disappearance curves of hCG and [125I]hCG showed similar paths
until relapse was evidenced by a discrepancy between the curve of
[125I]hCG and the curve of immunologically measured hCG. In the
third relapsing patient, the disappearance curves of hCG and
[125I]hCG also showed a similar path until hCG was below 2 IU l–1.
The patient relapsed with increasing hCG 13 months after start of
chemotherapy. In the remaining patient (no. 22) who experienced
relapse, the disappearance curves of hCG and [125I]hCG did not
have a similar shape.
By using the steep part of the hCG plasma disappearance curve,
five good-risk patients (nos. 8, 10, 15, 18 and 19) and two poor-risk
patients (nos. 4 and 9) had half-lives longer than 3 days, i.e. 3.2,
3.8, 4.7, 6.7, 3.6, 4.0 and 3.5 days respectively. All these patients
achieved long-term remission after CR (five patients) or SCR (two
patients). Three out of four patients, who had a relapse (nos. 6, 11
and 14) had half-lives shorter than 3 days, i.e. 2.8, 2.6 and 2.6 days.
The remaining patient (no. 22) had a half-life of 3.7 days.
In 12 patients (nos. 2, 5, 7, 9, 11, 14, 17, 19, 20, 22, 26 and 27),
hCG was elevated (> 2 IU l–1) before the start of the fourth cycle of
chemotherapy. The apparent half-lives of hCG between the third
and fourth cycles of chemotherapy in these patients were between
7.4 and 17.0 days. Despite the prolonged half-life of hCG, 8 of
these 12 patients were in continuous remission during follow-up.
Three patients (nos. 11, 14 and 22) had a relapse and one patient
(no. 27) died as a result of toxicity from treatment.
Four patients (nos. 2, 5, 7 and 26) had elevated hCG (> 2 IU per
l) in plasma up to 150 days after the fourth cycle of chemotherapy.
Three patients achieved an SCR (nos. 2, 7 and 26), and one contin-
uous remission after a partial response (PR) (no. 5, see below).
The disappearance of immunologically measured hCG and of
[125I]hCG in these four patients was similar, and the slow hCG
decline was ascribed to a slow plasma disappearance and not to a
continuous formation of hCG from vital tumour cells. All four
patients became hCG negative (< 2 IU l–1) without additional
chemotherapy and were in continuous remission for 48+, 44+, 39+
and 12+ months, respectively, after initiation of chemotherapy.
When the present study was initiated, the treatment strategy in
Denmark was to give one or two extra cycles of chemotherapy if
hCG was not normalized and decreased with a half-life longer than
3 days before the fourth treatment cycle. Using this recommended
treatment strategy, eight poor-risk patients (nos. 2, 5, 7, 9, 11, 14,
22 and 26) and one good-risk patients (no. 17) were considered for
additional/intensified chemotherapy. These patients all had an
elevated plasma concentration and a prolonged half-life of hCG
when starting the fourth cycle of chemotherapy as well as after
completing the four treatment cycles. In patient no. 22, who
progressed during chemotherapy, the disappearance curves for
hCG and [125I]hCG deviated. This patient refused further
chemotherapy and died 7 months after initiation of chemotherapy.
In the other eight patients, the disappearance curves for hCG and
[125I]hCG had similar paths before and after the four cycles of
chemotherapy. Hence, no further chemotherapy was given. The
good-risk patient (no. 17) achieved an SCR and was alive with no
evidence of disease 22+ months after initiation of chemotherapy.
Similarly, four out of the seven poor-risk patients (nos. 2, 7, 9 and
26) achieved an SCR. They were all alive with no evidence of
disease 48+, 39+, 36+ and 12+ months, respectively, after initia-
tion of chemotherapy. One of the poor-risk patients (no. 5) had
metastases to retroperitoneal lymph nodes, lungs, liver and spleen.
He achieved a partial response. Residual tumours in lungs, liver
and spleen were inaccessible for radical surgery. However,
multiple biopsies revealed only necrosis and fibrosis. This patient
was alive with further and continuous remission 44+ months after
initiation of chemotherapy.
The remaining two poor-risk patients (nos. 11 and 14) considered
for additional chemotherapy had a relapse with increasing hCG
concentrations shortly after completion of the fourth cycle of
chemotherapy. This was evidenced by a discrepancy between the
disappearance of [125I]hCG and total hCG. One of the patients
refused further chemotherapy and died after 9 months. The other
patient had supralethal chemotherapy followed by autologous bone
marrow transplantation. He relapsed again, with increasing hCG
plasma concentration, 30 days after treatment and died 13 months
after initiation of the primary chemotherapy.
DISCUSSION
A half-life of hCG longer than 3 days during chemotherapy for
testicular cancer has been used to identify patients with a high risk
of relapse and who are thus candidates for intensified therapy
(Toner et al, 1990; Motzer et al, 1992; Bosl, 1993; Motzer et al,
1993; Bosl and Chaganti, 1994; Murphy et al, 1994; Gerl et al,
1996; Bosl and Motzer, 1997). On the other hand, Horwich &
Peckham (1984), Stevens et al (1995), de Wit et al (1997) and Zon
et al (1998) did not find any association between response to
chemotherapy and a prolonged half-life of hCG longer than 3 days.
The plasma disappearance of hCG may depend on treatment-
induced toxicity on elimination organs, changes in volume of
distribution of hCG caused by loss of weight, disease-induced
changes in elimination, receptor or unspecific binding of hCG in
different tissues or varying production or release of hCG from
tumour cells during therapy. Because of these factors, we consid-
ered the commonly used monoexponential model for the disap-
pearance of hCG with an acceptable half-life of less than 3 days to
be too simplistic.
The present study indicates that the plasma disappearance of
hCG during chemotherapy can be quite different from the
commonly used monoexponential model. In all patients, a biphasic
plasma disappearance with an initial fast and a late slow phase was
observed. Serial measurements of hCG from 13 patients receiving
chemotherapy showed a half-life of hCG between the third and
fourth treatment cycle longer than 3 days. Despite this ‘prolonged’
half-life, all 13 patients were in continuous remission ranging from
12+ to 48+ months after completion of chemotherapy. This is in125I-labelled hCG as an elimination marker 1581
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accordance with data reported by Andreyev et al (1993) and Zon et
al (1998) and substantiates our observation that a slow half-life of
hCG late during or after treatment is not necessarily associated
with vital hCG-producing tumour cells. Others have used the
initial half-life to select patients for intensified chemotherapy
(Toner et al, 1990; Bosl, 1993; Motzer et al, 1993). In our study,
an initial half-life longer than 3 days did not predict the outcome
of chemotherapy. Thus, seven patients who achieved long-term
remission had initial half-lives longer than 3 days. In contrast, we
found an initial half-life shorter than 3 days in three out of four
patients who had a relapse.
To address the question of whether a slow decline of hCG
during chemotherapy is caused by continuous production of hCG
from vital tumour cells or a slow plasma disappearance, we used
[125I]hCG as an elimination marker. Monitoring [125I]hCG gave us
a model for the disappearance of hCG under the assumption of no
production of hCG. This allowed us to consider the plasma disap-
pearance of hCG regardless of treatment or other interfering
factors. If the curve of immunologically measured hCG showed a
slow disappearance but was similar in shape to the disappearance
of [125I]hCG, we interpreted the prolonged half-life as caused by a
slow plasma disappearance rather than a production of hCG from
vital tumour cells. This seems to be in accordance with the subse-
quent outcome for the majority of patients, although it should be
emphasized that this pattern does not ensure long-term survival.
The study suggests that the concept of a fixed half-life or
apparent half-life of hCG based on immunological hCG measure-
ments during chemotherapy may be misleading. Thus, a threshold
value of a hCG half-life of 3 days may lead to serious mistakes
when deciding further treatment. We recommend that decision on
further treatment should be based on inspection of a curve of
frequently measured plasma hCG concentrations rather than on
calculation of hCG half-lives. The use of [125I]hCG plasma disap-
pearance curves may be helpful in the interpretation of the results.
If the disappearance curves correspond, a so-called prolonged
half-life of hCG and persistence of hCG in plasma does not by
itself justify a change of the treatment strategy.
ABBREVIATIONS
hCG, gonadotropin chorionic (human); NED, no evidence of
disease; CR, complete remission; SCR, surgical complete remis-
sion (defined as: residual tumour removed by surgery and
histopathological examination including microscopy showing only
necrosis or fibrosis or mature teratoma. If mature teratoma is found
in the residual tumour, the operation should be radical for fulfilling
the criteria of an SCR); PR, partial remission; PD, progressive
disease; RPLND, retroperitoneal lymph node dissection; CD,
conventional dose chemotherapy; HD, high-dose chemotherapy;
DL, detection limit.
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